170 related articles for article (PubMed ID: 7250179)
1. Effect of urine pH and flow on renal clearance of methotrexate.
Sand TE; Jacobsen S
Eur J Clin Pharmacol; 1981; 19(6):453-6. PubMed ID: 7250179
[TBL] [Abstract][Full Text] [Related]
2. Outcomes Associated with Reducing the Urine Alkalinization Threshold in Patients Receiving High-Dose Methotrexate.
Drost SA; Wentzell JR; Giguère P; McLurg DL; Sabloff M; Kanji S; Nguyen TT
Pharmacotherapy; 2017 Jun; 37(6):684-691. PubMed ID: 28394433
[TBL] [Abstract][Full Text] [Related]
3. Theoretically required urinary flow during high-dose methotrexate infusion.
Sasaki K; Tanaka J; Fujimoto T
Cancer Chemother Pharmacol; 1984; 13(1):9-13. PubMed ID: 6733846
[TBL] [Abstract][Full Text] [Related]
4. Urinary pH and urine flow independent renal clearance of methotrexate in dogs.
Lui CY; Lee MG; Chiou WL
J Pharmacokinet Biopharm; 1985 Apr; 13(2):159-71. PubMed ID: 4057055
[TBL] [Abstract][Full Text] [Related]
5. Antineoplastic agents: high-dose methotrexate and citrovorum factor rescue.
Sadée W
Ther Drug Monit; 1980; 2(2):177-85. PubMed ID: 6762711
[TBL] [Abstract][Full Text] [Related]
6. High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL).
Skärby T; Jönsson P; Hjorth L; Behrentz M; Björk O; Forestier E; Jarfelt M; Lönnerholm G; Höglund P
Cancer Chemother Pharmacol; 2003 Apr; 51(4):311-20. PubMed ID: 12721759
[TBL] [Abstract][Full Text] [Related]
7. Clearance studies of methotrexate and 7-hydroxy-methotrexate in rabbits after multiple-dose infusion.
Chen ML; Chiou WL
J Pharmacokinet Biopharm; 1983 Oct; 11(5):515-27. PubMed ID: 6668557
[TBL] [Abstract][Full Text] [Related]
8. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.
Mikkelsen TS; Mamoudou AD; Tuckuviene R; Wehner PS; Schroeder H
Pediatr Blood Cancer; 2014 Feb; 61(2):297-301. PubMed ID: 24039194
[TBL] [Abstract][Full Text] [Related]
9. Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine.
Abelson HT; Fosburg MT; Beardsley GP; Goorin AM; Gorka C; Link M; Link D
J Clin Oncol; 1983 Mar; 1(3):208-16. PubMed ID: 6607976
[TBL] [Abstract][Full Text] [Related]
10. [Renal excretion of methotrexate in an in vivo model in minipigs].
Cermanová J; Chládek J; Sispera L; Martínková J
Acta Medica (Hradec Kralove) Suppl; 2000; 43(2):139-47. PubMed ID: 11413676
[TBL] [Abstract][Full Text] [Related]
11. The effects of antibiotics and uricosuric drugs on the renal elimination of methotrexate and 7-hydroxymethotrexate in rabbits.
Iven H; Brasch H
Cancer Chemother Pharmacol; 1988; 21(4):337-42. PubMed ID: 3370743
[TBL] [Abstract][Full Text] [Related]
12. Effect of hydration on methotrexate plasma concentrations in children with acute lymphocytic leukemia.
Christensen ML; Rivera GK; Crom WR; Hancock ML; Evans WE
J Clin Oncol; 1988 May; 6(5):797-801. PubMed ID: 3163362
[TBL] [Abstract][Full Text] [Related]
13. Renal clearance of methotrexate in man during high-dose oral and intravenous infusion therapy.
Christophidis N; Louis WJ; Lucas I; Moon W; Vajda FJ
Cancer Chemother Pharmacol; 1981; 6(1):59-64. PubMed ID: 7273267
[TBL] [Abstract][Full Text] [Related]
14. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
[TBL] [Abstract][Full Text] [Related]
15. [Renal tubular dysfunction in patients with rheumatoid arthritis starting with low dose of methotrexate].
Wiland P; Wiela-Hojeńska A; Swierkot J; Hurkacz M; Orzechowska-Juzwenko K; Szechiński J
Pol Arch Med Wewn; 2003 Aug; 110(2):855-62. PubMed ID: 14682224
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous Determination of Urine Methotrexate, 7-Hydroxy Methotrexate, Deoxyaminopteroic Acid, and 7-Hydroxy Deoxyaminopteroic Acid by UHPLC-MS/MS in Patients Receiving High-dose Methotrexate Therapy.
Mei S; Cui Y; Zhang D; Zeng C; Ren X; Yu K; Lin S; Zhao Z
Anal Sci; 2020 Dec; 36(12):1479-1483. PubMed ID: 32801284
[TBL] [Abstract][Full Text] [Related]
17. Clearance studies of methotrexate in dogs after multiple-rate infusion.
Lui CY; Lee MG; Chiou WL
Cancer Res; 1985 Apr; 45(4):1545-8. PubMed ID: 3978622
[TBL] [Abstract][Full Text] [Related]
18. Creatinine clearance rate and serum creatinine concentration are related to delayed methotrexate elimination in children with lymphoblastic malignancies.
Mao J; Zhang L; Shen H; Tang Y; Song H; Zhao F; Xu W
Neoplasma; 2014; 61(1):77-82. PubMed ID: 24195512
[TBL] [Abstract][Full Text] [Related]
19. Use of the automatic interaction detector method to identify patient characteristics related to methotrexate clearance.
Crom WR; Glynn AM; Abromowitch M; Pui CH; Dodge R; Evans WE
Clin Pharmacol Ther; 1986 May; 39(5):592-7. PubMed ID: 3516513
[TBL] [Abstract][Full Text] [Related]
20. Methotrexate Associated Renal Impairment Is Related to Delayed Elimination of High-Dose Methotrexate.
Yang SL; Zhao FY; Song H; Shen DY; Xu XJ
ScientificWorldJournal; 2015; 2015():751703. PubMed ID: 26185782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]